Event reduction: Revisiting why we treat with statins and harnessing current evidence towards optimal therapy

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 1, 2011, Pages 99-117

  Weart, Charles Wayne ^a   Hogan, Richard J ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Envision House   (United Kingdom)

Author keywords

Dyslipidemia; Evidence based medicine; Lipids; Statins

Indexed keywords

ATORVASTATIN; CLARITHROMYCIN; COLESTYRAMINE; COUMARIN; CYCLOSPORIN; DIGOXIN; ERYTHROMYCIN; ETHINYLESTRADIOL; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FLUCONAZOLE; FLUINDOSTATIN; GEMFIBROZIL; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LAROPIPRANT PLUS NICOTINIC ACID; LOPINAVIR; MEVINOLIN; NICOTINIC ACID; NORETHISTERONE ACETATE; PHENYTOIN; PITAVASTATIN; PRAVASTATIN; RIFAMPICIN; RITONAVIR PLUS SAQUINAVIR; ROSUVASTATIN; SIMVASTATIN; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEDTIME DOSAGE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DYSLIPIDEMIA; EVENING DOSAGE; HEART INFARCTION; HEMATURIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIFESTYLE MODIFICATION; MEDLINE; MEMORY DISORDER; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; PATIENT COMPLIANCE; PROTEINURIA; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; TRANSIENT ISCHEMIC ATTACK;

CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PRIMARY PREVENTION;

EID: 78650462735     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.516747     Document Type: Review

References (120)

1. Keys A, Karvonen MJ, Punsar S, et al. HDL serum cholesterol and 24-year mortality of men in Finland. Int J Epidemiol 1984;13:428-35
2. Pocock SJ, Shaper AG, Phillips AN, et al. High density lipoprotein cholesterol is not a major risk factor for ischaemic heart disease in British men. Br Med J (Clin Res Ed) 1986;292:515-19
3. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-72
4. Shaughnessy AF, Slawson DC, Bennett JH. Becoming an information master: a guidebook to the medical information jungle. J Fam Pract 1994;39:489-99
5. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7
6. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22
7. Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 2010;170:1024-31
8. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57
9. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events trial investigators. N Engl J Med 1996;335:1001-9
10. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
11. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001, 285: 2486-97
12. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
13. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30
14. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58 (Pubitemid 36398384)
15. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
16. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
17. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-18
18. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007
19. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
20. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007;28:2375-414
21. Teramoto T, Sasaki J, Ueshima H, et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007;14:45-50
22. Joint Committee for Developing Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults. Chinese guidelines on prevention and treatment of dyslipidemia in adults. Zhonghua Xin Xue Guan Bing Za Zhi 2007;35:390-419
23. Enas EA, Singh V, Munjal YP, et al. Recommendations of the Second Indo-U.S. Health Summit on Prevention and Control of Cardiovascular Disease among Asian Indians. Indian Heart J 2009;61:265-74
24. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
25. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45
26. Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. J Am Coll Cardiol 2004;44:1772-9
27. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-72 (Pubitemid 43947981)
28. American Heart Association and the American College of Cardiology. Joint statement from the American Heart Association and the American College of Cardiology on the ENHANCE trial. 31 March 2008. Available from: http:// americanheart.mediaroom.com/index. php?s=43&item=386 [Last accessed 8 April 2010]
29. Murphy SA, Cannon CP, Wiviott SD, et al. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes: from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol 2009;54:2358-62
30. Tikkanen MJ, Szarek M, Fayyad R, et al. Total cardiovascular disease burden: comparing intensive with moderate statin therapy: insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. J Am Coll Cardiol 2009;54:2353-7
31. Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-67
32. ORegan C, Wu P, Arora P, et al. Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med 2008;121:24-33
33. Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2006;113:e873-923 (Pubitemid 44313581)
34. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 2006;113:e409-49 (Pubitemid 43739468)
35. Amarenco P, Bogousslavsky J, Callahan A III, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59
36. Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008;39:1647-52
37. Goldstein LB, Amarenco P, Szarek M, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008;70:2364-70
38. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26
39. Biasucci LM. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation 2004;110:e560-7
40. Smith SC Jr, Anderson JL, Cannon RO III, et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the Clinical Practice Discussion Group. Circulation 2004;110:e550-3
41. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8
42. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
43. de Lorgeril M, Salen P, Abramson J, et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med 2010;170:1032-6
44. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61
45. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-9
46. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34
47. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 2009;32(Suppl 1):S13-61
48. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008;31:811-22
49. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
50. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
51. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25
52. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003;41:I-IV, S1-91
53. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004;110:1557-63
54. Shepherd J, Kastelein JJ, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008;51:1448-54 (Pubitemid 351471787)
55. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48 (Pubitemid 41058323)
56. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-407
57. Sharma M, Ansari MT, Abou-Setta AM, et al. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med 2009;151:622-30
58. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92
59. AIM-HIGH Investigators. Niacin plus statin to prevent vascular events. July 2005. Available from: http://www. clinicaltrials.gov/ct/show/NCT00120289 [Last accessed 8 April 2010]
60. HPS2-THRIVE Investigators. Treatment of HDL to reduce the incidence of vascular events. April 2007. Available from: http://www.clinicaltrials. gov/ct/show/NCT00461630 [Last accessed 10 August 2010]
61. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74
62. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8
63. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-56
64. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int 2003;63(Suppl 84):S207-10
65. Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/ simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008;156:826-32
66. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-22
67. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther 2006;28:26-35
68. Newman C, Tsai J, Szarek M, et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006;97:61-7
69. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16
70. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med 2008;359:789-99
71. US Food and Drug Administration. FDA Drug Safety Communication: Ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury. 19 March, 2010. Available from: http://www.fda.gov/ Drugs/DrugSafety/ PostmarketDrugSafetyInformationfor PatientsandProviders/ucm204882.htm [Last accessed 17 June 2010]
72. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006;97:89C-94C
73. AstraZeneca Pharmaceuticals LP. Crestor- (rosuvastatin calcium) tablets. US prescribing information. February 2010. Available from: http://www1. astrazeneca-us.com/pi/crestor.pdf [Last accessed 8 April 2010]
74. Bristol-Myers Squibb Company. Pravachol- (pravastatin sodium) tablets. US prescribing information. March 2007. Available from: http:// packageinserts.bms.com/pi/pi-pravachol. pdf [Last accessed 8 April 2010]
75. Kowa Pharmaceuticals America, Inc. Livalo- (pitavastatin) tablets. US prescribing information. January 2010. Available from: http://www. kowapharma.com/documents/ LIVALOpitavastatinprescribing informationV1-220100131. pdf [Last accessed 6 August 2010]
76. Merck & Co., Inc. Mevacor- (lovastatin) tablets. US prescribing information. October 2009. Available from: http://www.merck. com/product/usa/pi-circulars/m/mevacor/ mevacor-pi.pdf [Last accessed 8 April 2010]
77. Merck & Co., Inc. Zocor- (simvastatin) tablets. US prescribing information. March 2010. Available from: http://www.merck.com/product/ usa/pi-circulars/z/zocor/zocor-pi.pdf [Last accessed 8 April 2010]
78. Novartis Pharmaceuticals Corp. Lescol- (fluvastatin sodium) capsules. US prescribing information. October 2006. Available from: http://www.pharma.us. novartis.com/product/pi/pdf/Lescol.pdf [Last accessed 8 April 2010]
79. Pfizer, Inc. Lipitor- (atorvastatin calcium) tablets. US prescribing information. June 2009. Available from: http://www.pfizer.com/files/ products/uspi-lipitor.pdf [Last accessed 8 April 2010]
80. Jacobson TA. Toward pain-free statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008;83:687-700
81. Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 2006;97:44C-51C
82. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 2006;97:69C-76C
83. Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. Am J Cardiol 2004;94:935-8
84. Corsini A, Bellosta S, Davidson MH. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol 2005;96:44K-9K
85. Abbott Laboratories. Trilipix- (fenofibric acid) delayed release capsules. US prescribing information. December 2008. Available from: http://www. rxabbott.com/pdf/trilipix-pi.pdf [Last accessed 12 August 2010]
86. Nawarskas JJ. HMG-CoA reductase inhibitors and coenzyme Q10. Cardiol Rev 2005;13:76-9
87. Oh J, Ban MR, Miskie BA, et al. Genetic determinants of statin intolerance. Lipids Health Dis 2007;6:7
88. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
89. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/ NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-72
90. Mohaupt MG, Karas RH, Babiychuk EB, et al. Association between statin-associated myopathy and skeletal muscle damage. CMAJ 2009;181:E11-18
91. Kasiske BL, Wanner C, ONeill WC. An assessment of statin safety by nephrologists. Am J Cardiol 2006;97:82C-5C
92. AstraZeneca Pharmaceuticals LP. Clinical study report synopsis. A randomized, double-blind, 52-week, parallel-group, multicenter, phase IIb study to evaluate the effects of rosuvastatin 10 mg, rosuvastatin 40 mg, and atorvastatin 80 mg on urinary protein excretion in hypercholesterolemic diabetic patients with moderate proteinuria. PLANET I: Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients with Progressive Renal Disease. February 2010. Available from: http://www. clinicalstudyresults.org/ documents/ company-study-10042-0.pdf [Last accessed 13 August 2010]
93. AstraZeneca Pharmaceuticals LP. Clinical study report synopsis. A randomized, double-blind, 52-week, parallel-group, multicenter, phase IIb study to evaluate the effects of rosuvastatin 10 mg, rosuvastatin 40 mg, and atorvastatin 80 mg on urinary protein excretion in hypercholesterolemic non-diabetic patients with moderate proteinuria. PLANET II: Prospective Evaluation of Proteinuria and Renal Function in Non-Diabetic Patients with Progressive Renal Disease. March 2010. Available from: http://www. clinicalstudyresults.org/documents/ company-study-10043-1.pdf [Last accessed 13 August 2010]
94. Vidt DG, Cressman MD, Harris S, et al. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004;102:52-60
95. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006;17:2006-16
96. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 2007;50:409-18
97. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006;97:77C-81C
98. Snow V, Aronson MD, Hornbake ER, et al. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2004;140:644-9
99. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med, 2008,359: 1357-66
100. Alsheikh-Ali AA, Trikalinos TA, Kent DM, Karas RH. Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol 2008;52:1141-7
101. Meade TW, Brennan PJ. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ 2000;321:13-17
102. Brass LM, Alberts MJ, Sparks L. An assessment of statin safety by neurologists. Am J Cardiol 2006;97:86C-88C
103. Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy 2009;29:800-11
104. Redelmeier DA, Thiruchelvam D, Daneman N. Delirium after elective surgery among elderly patients taking statins. CMAJ 2008;179:645-52
105. Golomb BA, Criqui MH, White HL, Dimsdale JE. The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. Control Clin Trials 2004;25:178-202
106. Coleman CI, Reinhart K, Kluger J, White CM. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2008;24:1359-62
107. Kahn R, Robertson RM, Smith R, Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Circulation 2008;118:576-85
108. Gade P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93
109. Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 2005;96:556-63
110. Waters DD, Brotons C, Chiang CW, et al. Lipid Treatment Assessment Project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009;120:28-34
111. Gehi AK, Ali S, Na B, Whooley MA. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the Heart and Soul Study. Arch Intern Med 2007;167:1798-803
112. Hess G, Sanders KN, Hill J, Liu LZ. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin. Am J Manag Care 2007;13(Suppl 3):S80-5
113. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in Project ImPACT: Hyperlipidemia. J Am Pharm Assoc (Wash DC) 2000;40:157-65
114. Bunting BA, Smith BH, Sutherland SE. The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia. J Am Pharm Assoc 2008;48:23-31
115. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000
116. Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007;298:776-85
117. Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005;294:326-33
118. Kastelein JJ, van der Steeg WA, Holme I, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008;117:3002-9
119. Strippoli GF, Craig JC. Sunset for statins after AURORA? N Engl J Med 2009;360:1455-7
120. Masoudi FA. Statins for ischemic systolic heart failure. N Engl J Med 2007;357: 2301-4